Stimulation of bone formation by zoledronic acid in particle-induced osteolysis.
We investigated the effect of a single subcutaneous dose of zoledronic acid on particle-induced osteolysis and observed excessive regional new bone formation. We utilized the murine calvarial osteolysis model and polyethylene particles in C57BL/J6 mice. Twenty-eight mice were used, seven per group. Specimens were stained with Giemsa dye. The osteoid tissue area was determined. Bone thickness was measured as an indicator of bone growth. Net bone growth was significantly increased in animals with zoledronic acid treatment: 0.02 mm(2)+/-0.03 mm(2) in animals with particle implantation only (group 2), 0.25 mm(2)+/-0.08 mm(2) with particle implantation and zoledronic acid treatment directly after surgery (group 3; p=0.0018), and 0.21 mm(2)+/-0.11 mm(2) with particle implantation and zoledronic acid treatment on the fourth postoperative day (group 4; p=0.0042). The mean bone thickness was 0.2 mm+/-0.04 mm (range 0.17 mm-0.31 mm) in group 1 (sham controls) and 0.16 mm+/-0.02 mm (range 0.14 mm-0.19 mm) in group 2, 0.31 mm+/-0.04 mm (range 0.28 mm-0.39 mm) in group 3, and 0.29 mm+/-0.02 mm (range 0.28 mm-0.34 mm) in group 4. Student's t-test revealed a statistically significant difference between groups 2 and 3 (p=0.00042), and groups 2 and 4 (p=0.0019). In conclusion, our observational study suggests that zoledronic acid may stimulate bone apposition locally in the process of particle-induced osteolysis.
Wedemeyer
Christian
C
Department of Orthopaedics, University of Duisburg-Essen, Pattbergstrasse 1-3, D-45239 Essen, Germany.
von Knoch
Fabian
F
Pingsmann
Andreas
A
Hilken
Gero
G
Sprecher
Christoph
C
Saxler
Guido
G
Henschke
Frank
F
Löer
Franz
F
von Knoch
Marius
M
D000818:Animals; D004164:Diphosphonates / Q000008:administration & dosage*; D005549:Foreign-Body Reaction / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control; D007093:Imidazoles / Q000008:administration & dosage*; D051379:Mice; D008810:Mice, Inbred C57BL; D010012:Osteogenesis / Q000187:drug effects*; D010014:Osteolysis / Q000139:chemically induced / Q000473:pathology* / Q000517:prevention & control*; D010316:Particle Size; D011095:Polyethylenes / Q000009:adverse effects*; D011475:Prosthesis Failure; D016459:Prosthesis-Related Infections / Q000139:chemically induced / Q000517:prevention & control; D012886:Skull / Q000187:drug effects* / Q000473:pathology*; D016896:Treatment Outcome; D000077211:Zoledronic Acid
D004164:Diphosphonates; D007093:Imidazoles; D011095:Polyethylenes; C111601:ultra-high molecular weight polyethylene; D000077211:Zoledronic Acid